Eli Lilly arthritis drug helped hospitalized COVID-19 patients recover faster

Backed by clinical trial data, Eli Lilly and Incyte Corp. will pursue emergency use authorization for their rheumatoid arthritis drug baricitinib (Olumiant) as a treatment for COVID-19. Previous research has demonstrated that certain steroids, owing to their anti-inflammatory properties, may benefit infected patients.

Backed by clinical trial data, Eli Lilly and Incyte Corp. will pursue emergency use authorization for their rheumatoid arthritis drug baricitinib (Olumiant) as a treatment for COVID-19. Previous research has demonstrated that certain steroids, owing to their anti-inflammatory properties, may benefit infected patients. The new study, which involved more than 1,000 people, paired Olumiant—which inhibits proteins implicated in inflammation—with the antiviral medication remdesivir (Verkury—Gilead Sciences). Compared with remdesivir alone, the findings suggest, hospitalized patients recovered about 1 day sooner when remdesivir was combined with baricitinib. Although the actual timeline was not revealed, other research has estimated recovery time with remdesivir at a median 11 days. Additional studies this year have ruled out anti-inflammatory drugs from Roche Holding, Regeneron Pharmaceuticals, and Sanofi as potential COVID-19 therapies.